Financial Tear Sheet

Corporate Profile

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

More Information

Primary IR Contact
Clarissa Willett
Vice President, Investor Relations
Laboratory Corporation of America Holdings
Phone: 336-436-5076
Fax: 336-436-1569
E-mail: investor@labcorp.com

Stock Performance
LH (Common)
ExchangeNYSE (US Dollar)
Price$145.22
Change (%) Stock is Up 1.06 (0.74%)
Volume1,373,986
52 Week Low$119.38
Market Cap$14,330,049,656
Rolling EPS8.61
PE Ratio16.8664
Shares Outstanding98,678,210
Data as of 04/18/19 4:02 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: LH.  Currently trading at $145.22 with a 52 week high of $190.35 and a 52 week low of $119.38.
Recent News & Events
04/17/19 - 5:05 p.m.
LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
04/01/19 - 8:45 a.m.
LabCorp to Announce First Quarter Financial Results on April 30, 2019
04/01/19 - 8:15 a.m.
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
DateTitle
04/30/19 9:00 a.m. ET
Q1 2019 Laboratory Corporation of America Holdings Earnings Conference Call
Analyst Estimates / Ratings
Mean Recommendation: 2.4

Buy
SellStrong Buy
Unable to fulfill request.
SEC Filings
Filing DateForm
04/18/198-K XBRL SEC Filing Unavailable
04/10/19SC 13G/A XBRL SEC Filing Unavailable
04/05/193 XBRL SEC Filing Unavailable
04/05/194 XBRL SEC Filing Unavailable
Corporate Governance
David P.  KingChairman and Chief Executive Officer
Glenn A. EisenbergExecutive Vice President and Chief Financial Officer
John D.  RatliffChief Executive Officer, Covance Drug Development
Lance V. BerberianSenior Vice President and Chief Information Officer
Edward T. DodsonSenior Vice President and Chief Accounting Officer
Sandra D. van der VaartSenior Vice President, Global General Counsel
Lisa J. UthgenanntChief Human Resources Officer
Brian J. CaveneyChief Medical Officer
Ownership Summary
Shareholders
 HoldersValue ($MM)% O/SShares
Institution1,03812,022.8495.093,747,334
Mutual Fund1,5847,103.4848.748,100,067
Insider *1976.530.5523,827
*Insider values reflect direct beneficial ownership.
Top Holders
 Shares Held% O/SShare ChangeFiling Date
The Vanguard Group, Inc.10,880,74311.057,07612/31/18
BlackRock Institutional Trust Company, N.A.5,940,2476.0296,01812/31/18
State Street Global Advisors (US)4,254,3034.34,52712/31/18
Boston Partners3,269,2683.3-1,195,80612/31/18
Nordea Funds Oy2,120,5092.2143,42612/31/18
Amundi Pioneer Asset Management, Inc.1,524,3951.5-400,85912/31/18
JP Morgan Asset Management1,484,8671.516,87112/31/18
Dimensional Fund Advisors, L.P.1,460,2141.534,79712/31/18
Geode Capital Management, L.L.C.1,412,0931.4111,85912/31/18
BlackRock Investment Management, LLC1,250,9381.3133,66412/31/18